Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice

Authors:

Abstract
The ORFs of both native and codon‐optimized E7 genes were successfully fused to SPusp45 signal peptide and expressed by a nisin‐controlled gene expression system in the NZ9000 strains of Lactococcus lactis. Recombinant strains were confirmed by Western blot analysis. To measure immune responses against the E7 antigen, specific‐pathogen‐free C57BL/6 mice were inoculated with L lactis harboring pNZ8123‐rE7 by oral gavage. Then, specific antibodies and cytokines were measured by enzyme‐linked immunosorbent assay and enzyme‐linked immunospot assay, respectively. Oral administration of L lactis strains expressing rE7 elicited the highest levels of E7‐specific antibody and greatest numbers of E7‐specific CD4+ T helper and CD8+ T cell precursors. Our outcomes indicated that the HPV‐16 E7 specific IL‐2‐ and IFN‐γ‐secreting T cells in antigen‐stimulated splenocytes and intestinal mucosal lymphocytes were significantly higher than the control groups. Our data also demonstrated that mice vaccinated with recombinant L lactis were able to generate potent protective effects against challenge with the E7‐expressing tumor cell line (TC‐1). Moreover, L lactis containing pNZ8123‐HPV16‐optiE7 showed strong therapeutic antitumor effects against established tumors in vivo. These findings demonstrate that recombinant L lactis induce both humoral and cellular immune responses in mice and are therefore recommended for therapeutic treatments in humans after oral administration.

This publication has 38 references indexed in Scilit: